EUCTR2021-006326-48-DE进行中（未招募）1 期
A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •? Age 6 months to <18 years at the time of signing Informed Consent for Part 1 and Cohort B of the study, and age 6 months to <=30 years old at the time of signing Informed Consent for Part 2 of the study
- •? Histologically re-confirmed diagnosis, via tissue biopsy, or bone marrow aspirate, pleural effusion, or ascites, prior to study entry of aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) that expresses CD20 (reconfirmed by immunohistochemistry [IHC]), or flow cytometry if IHC is not possible including Burkitt lymphoma (BL), Burkitt leukemia (BAL) (mature B-cell leukemia fragment antigen-binding [FAB] L3), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL), at the time of first relapsed or refractory (R/R) disease for Cohort A and second or greater R/R disease for Cohort B
- •? Refractory or relapsed disease (i.e., prior treatment was ineffective or intolerable) following first-line standard-of-care chemoimmunotherapy for Cohort A and following at least two prior systemic chemoimmunotherapy regimens and who have exhausted all available established therapies for Cohort B
- •? Measurable disease
- •? Adequate performance status, as assessed according to the Lansky or Karnofsky Performance Status scales
- •? Adequate bone marrow function
- •? Adequate liver and renal function
- •? Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic hepatitis B virus (HBV) infection
- •? Negative test results for hepatitis C virus (HCV) and HIV
- •? For female participants of childbearing potential, or who will reach childbearing potential during the study: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for at least 18 months after obinutuzumab pretreatment, 2 months after the final dose of glofitamab, 12 months after the final dose of rituximab and/or ifosfamide, carboplatin, and etoposide (ICE), or 3 months after the final dose of tocilizumab
- •? For male participants who are expected to reach sexual maturity during the study, or have already reached sexual maturity by the screening visit: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm during the treatment period and for at least 3 months after pretreatment with obinutuzumab, 2 months after the final dose of glofitamab, 6 months after the final dose of rituximab and/or ICE, or 2 months after the last dose of tocilizumab (if applicable), whichever is longer, to avoid exposing the embryo
- •? Participants and/or caregivers who are willing and able to complete clinical outcome assessments throughout the study using either paper or interviewer methods
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 55
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Isolated CNS disease of mature B-NHL without systemic involvement, and primary central nervous system (CNS) lymphoma
- •? Receipt of glofitamab prior to study enrollment
- •? Ongoing adverse events from prior anti-cancer therapy that were not resolved to Grade <=1
- •? Participants with active infections which are not resolved prior to Day 1 of Cycle 1
- •? Grade >=3 adverse events, with the exception of Grade 3 endocrinopathy managed with replacement therapy
- •? Patients with active infections which are not resolved prior to Day 1 of Cycle 1
- •? Prior solid organ transplantation
- •? Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- •? Known or suspected chronic active Epstein-Barr viral infection (CAEBV)
- •? Active autoimmune disease requiring treatment
- •? History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
- •? History of confirmed progressive multifocal leukoencephalopathy
- •? Current or past history of uncontrolled non-malignant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- •? Evidence of significant and uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
- •? Major surgery or significant traumatic injury <28 days prior to the obinutuzumab pretreatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
- •? Administration of a live, attenuated vaccine within 4 weeks before the start of study treatment (obinutuzumab pretreatment) or at any time during the study treatment period and within 12 months after end of study treatment
- •? Participants with any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
- •? Pregnancy or breastfeeding, or intention of becoming pregnant during the study
- •Exclusion criteria applicable to Cohort A only
- •? Receipt of any R-ICE chemoimmunotherapy prior to study enrollment into Cohort A
- •? Receipt of more than one prior line of standard-of-care B-NHL chemoimmunotherapy
- •? Prior allogeneic or autologous stem cell transplantation (SCT)
- •Exclusion criteria applicable to Cohort B only
- •? Prior treatment with systemic chemotherapy and immunotherapeutic agents
- •? Patients with uncontrolled CNS involvement
- •? Prior allogeneic or autologous SCT <=100 days post-transplant prior to enrollment
- •? Presence of Grade >=2 acute or extensive chronic graft -versus-host disease (GVHD) in participants who received prior allogeneic hematopoietic stem cell transplantation (HSCT)
- •? Prior treatment with systemic immunosuppressive agents for treatment of GVHD, within 4 weeks or five half-lives of the drug, whichever is shorter, before the first GpT infusion
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaCD20 positive B-Cell Non-Hodgkin LymphomaMedDRA version: 23.1Level: LLTClassification code 10084346Term: B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2021-006326-48-DKF.Hoffmann-La Roche Ltd65
进行中（未招募）
1 期
A Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer’s DiseaseEUCTR2020-001384-87-ITF. HOFFMANN - LA ROCHE LTD.150
进行中（未招募）
1 期
A Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer’s DiseaseEUCTR2020-001384-87-DEF. Hoffmann-La Roche Ltd192
进行中（未招募）
1 期
A Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer’s DiseaseAlzheimer's Disease (AD)MedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10074616Term: Prodromal Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-001384-87-GBF. Hoffmann-La Roche Ltd150
进行中（未招募）
1 期
A Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer’s DiseaseAlzheimer's Disease (AD)MedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10074616Term: Prodromal Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-001384-87-FRF. Hoffmann-La Roche Ltd150